United States Drug Discovery Market Forecast 2022-2028

The United States drug discovery market is expected to register a CAGR of 6.26% during the forecast period, 2022-2028. The country is one of the lucrative drug discovery and development markets with the presence of several industry players.

MARKET INSIGHTS

In the United States, cancer and heart disease have been leading death causes for over a decade. Also, the rising prevalence of chronic diseases like diabetes, the increasing product launches by key players, and the growing use of drug delivery devices for disease management boost growth opportunities. For instance, as per the National Diabetes Statistics Report, there were almost 23 million people in the US in 2017. Therefore, the high prevalence of diabetes enables several drug delivery systems for treating diabetes patients.

Further, as per the American Cancer Society, around 1.8 million new cases were expected to be diagnosed in 2020. Additionally, there has been a surge in the usage of advanced technologies like combinatorial chemistry for better drug candidate identification, bioinformatics, and high throughput. Accordingly, drug discovery has evolved considerably with emerging technologies, rendering the process less time-consuming and more refined & accurate. Such prevailing health conditions and their overall impact lead to research institutes and pharma companies directing their research efforts to varied therapeutic areas to offer viable solutions.

COMPETITIVE INSIGHTS

Some of the prominent firms in the market include: Johnson & Johnson, Merck & Co Inc, Pfizer Inc, Agilent Technologies Inc, IQVIA Holdings Inc, Charles River Laboratories International Inc, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 44080

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. KEY GROWTH ENABLERS
2.5. KEY GROWTH CHALLENGES

3. KEY ANALYTICS

3.1. IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
3.2. KEY MARKET TRENDS
3.3. PORTER'S FIVE FORCES ANALYSIS
- 3.3.1. BUYERS POWER
- 3.3.2. SUPPLIERS POWER
- 3.3.3. SUBSTITUTION
- 3.3.4. NEW ENTRANTS
- 3.3.5. INDUSTRY RIVALRY
3.4. OPPORTUNITY MATRIX
3.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
- 3.5.1. DRUG DISCOVERY AND DEVELOPMENT
- 3.5.2. PRECLINICAL RESEARCH
- 3.5.3. CLINICAL RESEARCH
- 3.5.4. REGULATORY AUTHORITY REVIEW
- 3.5.5. POST MARKET SAFETY MONITORING
3.6. REGULATORY FRAMEWORK

4. MARKET BY DRUG TYPE

4.1. SMALL MOLECULE DRUG
4.2. BIOLOGIC DRUG

5. MARKET BY SERVICE

5.1. CHEMICAL SERVICES
5.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
5.3. BIOLOGICAL SERVICES
5.4. OTHER PHARMACEUTICAL SERVICES

6. MARKET BY END-USER

6.1. PHARMACEUTICAL COMPANIES
6.2. CONTRACT RESEARCH ORGANIZATIONS
6.3. RESEARCH INSTITUTES
6.4. OTHER END-USERS

7. MARKET BY TECHNOLOGY

7.1. HIGH THROUGHPUT SCREENING
7.2. SPECTROSCOPY
7.3. COMBINATORIAL CHEMISTRY
7.4. BIOCHIPS
7.5. PHARMACOGENOMICS AND PHARMACOGENETICS
7.6. BIOINFORMATICS
7.7. METABOLOMICS
7.8. NANOTECHNOLOGY
7.9. OTHER TECHNOLOGIES

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. MERGERS & ACQUISITIONS
- 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.3. PARTNERSHIPS & AGREEMENTS
- 8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
8.2. COMPANY PROFILES
- 8.2.1. AGILENT TECHNOLOGIES INC
- 8.2.2. CHARLES RIVER LABORATORIES INTERNATIONAL INC
- 8.2.3. IQVIA HOLDINGS INC
- 8.2.4. JOHNSON & JOHNSON
- 8.2.5. MERCK & CO INC
- 8.2.6. PFIZER INC

Product Code: 44080

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - UNITED STATES DRUG DISCOVERY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: UNITED STATES DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: UNITED STATES DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 5: UNITED STATES DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: UNITED STATES DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 7: UNITED STATES DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: UNITED STATES DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 9: UNITED STATES DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: UNITED STATES DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 11: LEADING PLAYERS OPERATING IN UNITED STATES DRUG DISCOVERY MARKET
TABLE 12: LIST OF MERGERS & ACQUISITIONS
TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 15: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: UNITED STATES DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: UNITED STATES DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2028 (IN $ MILLION)
FIGURE 7: UNITED STATES DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2028 (IN $ MILLION)
FIGURE 8: UNITED STATES DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: UNITED STATES DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 10: UNITED STATES DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 11: UNITED STATES DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 12: UNITED STATES DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 13: UNITED STATES DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: UNITED STATES DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 15: UNITED STATES DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2028 (IN $ MILLION)
FIGURE 16: UNITED STATES DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2028 (IN $ MILLION)
FIGURE 17: UNITED STATES DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2028 (IN $ MILLION)
FIGURE 18: UNITED STATES DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: UNITED STATES DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2028 (IN $ MILLION)
FIGURE 20: UNITED STATES DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2028 (IN $ MILLION)
FIGURE 21: UNITED STATES DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 22: UNITED STATES DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2028 (IN $ MILLION)
FIGURE 23: UNITED STATES DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2028 (IN $ MILLION)
FIGURE 24: UNITED STATES DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2028 (IN $ MILLION)
FIGURE 25: UNITED STATES DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2028 (IN $ MILLION)
FIGURE 26: UNITED STATES DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 27: UNITED STATES DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2028 (IN $ MILLION)